InflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates [Yahoo! Finance]
InflaRx N.V. (IFRX)
Last inflarx n.v. earnings: 8/14 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
inflarx.com/home/investors/press-releases/01-2018--inflarx-to-present-at-upcoming-investor-conferences.html
Company Research
Source: Yahoo! Finance
This compares to loss of $0.18 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -50%. A quarter ago, it was expected that this company would post a loss of $0.29 per share when it actually produced a loss of $0.14, delivering a surprise of 51.72%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. InflaRx , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted zero revenues for the quarter ended December 2023, missing the Zacks Consensus Estimate by 99.87%. This compares to zero revenues a year ago. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. InflaRx shares have added about 3.7% since the beginning of the year versus the S&P 500's gain of 9.5%. What's Next for InflaRx? While
Show less
Read more
Impact Snapshot
Event Time:
IFRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IFRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IFRX alerts
High impacting InflaRx N.V. news events
Weekly update
A roundup of the hottest topics
IFRX
News
- InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters EventGlobeNewswire
- Global Sepsis Therapeutics Strategic Research Report 2024: Market to Reach $7.1 Billion by 2030 - Market Receives Pulsating Impetus from North America, Asia-Pacific to Witness Fastest Growth [Yahoo! Finance]Yahoo! Finance
- InflaRx (NASDAQ: IFRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.MarketBeat
- InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans [Yahoo! Finance]Yahoo! Finance
- InflaRx Reports Full Year 2023 Results and Announces INF904 Development PlansGlobeNewswire
IFRX
Earnings
- 8/10/23 - Beat
IFRX
Analyst Actions
- 3/22/24 - HC Wainwright
IFRX
Sec Filings
- 4/25/24 - Form 6-K
- 4/4/24 - Form 6-K
- 3/21/24 - Form 6-K
- IFRX's page on the SEC website